Gilead Sciences, Inc. $GILD Stock Holdings Increased by Jones Financial Companies Lllp

Jones Financial Companies Lllp boosted its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 9.8% during the third quarter, according to its most recent disclosure with the SEC. The institutional investor owned 79,803 shares of the biopharmaceutical company’s stock after purchasing an additional 7,144 shares during the period. Jones Financial Companies Lllp’s holdings in Gilead Sciences were worth $8,944,000 at the end of the most recent reporting period.

Several other large investors have also recently added to or reduced their stakes in the stock. Csenge Advisory Group raised its holdings in shares of Gilead Sciences by 319.0% during the third quarter. Csenge Advisory Group now owns 21,394 shares of the biopharmaceutical company’s stock worth $2,375,000 after acquiring an additional 16,288 shares in the last quarter. Railway Pension Investments Ltd grew its stake in Gilead Sciences by 3.1% in the third quarter. Railway Pension Investments Ltd now owns 1,415,665 shares of the biopharmaceutical company’s stock valued at $157,139,000 after purchasing an additional 42,200 shares in the last quarter. TriaGen Wealth Management LLC acquired a new position in Gilead Sciences in the 3rd quarter worth about $1,274,000. Sector Gamma AS raised its stake in shares of Gilead Sciences by 15.9% during the 3rd quarter. Sector Gamma AS now owns 147,239 shares of the biopharmaceutical company’s stock worth $16,344,000 after purchasing an additional 20,239 shares in the last quarter. Finally, iA Global Asset Management Inc. lifted its holdings in shares of Gilead Sciences by 11.6% during the 3rd quarter. iA Global Asset Management Inc. now owns 221,890 shares of the biopharmaceutical company’s stock valued at $24,630,000 after buying an additional 23,046 shares during the last quarter. Institutional investors and hedge funds own 83.67% of the company’s stock.

Gilead Sciences Trading Up 2.1%

Shares of NASDAQ:GILD opened at $146.23 on Thursday. The company has a debt-to-equity ratio of 1.03, a quick ratio of 1.31 and a current ratio of 1.45. The stock’s 50-day moving average is $126.41 and its 200-day moving average is $120.40. The company has a market cap of $181.42 billion, a P/E ratio of 22.67, a P/E/G ratio of 0.76 and a beta of 0.36. Gilead Sciences, Inc. has a 52-week low of $93.37 and a 52-week high of $146.73.

Insider Transactions at Gilead Sciences

In other Gilead Sciences news, insider Johanna Mercier sold 3,000 shares of Gilead Sciences stock in a transaction that occurred on Thursday, January 15th. The stock was sold at an average price of $124.31, for a total value of $372,930.00. Following the transaction, the insider directly owned 103,221 shares of the company’s stock, valued at $12,831,402.51. The trade was a 2.82% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, CFO Andrew D. Dickinson sold 3,000 shares of the company’s stock in a transaction that occurred on Thursday, January 15th. The stock was sold at an average price of $124.31, for a total value of $372,930.00. Following the transaction, the chief financial officer owned 150,503 shares of the company’s stock, valued at approximately $18,709,027.93. This trade represents a 1.95% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last three months, insiders have sold 257,397 shares of company stock worth $33,385,512. Insiders own 0.27% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities analysts recently commented on the company. Wolfe Research increased their price objective on Gilead Sciences from $150.00 to $155.00 and gave the stock an “outperform” rating in a report on Wednesday, January 28th. Wells Fargo & Company increased their price target on shares of Gilead Sciences from $145.00 to $150.00 and gave the stock an “overweight” rating in a research note on Wednesday, December 10th. HSBC lifted their price objective on shares of Gilead Sciences from $110.00 to $133.00 and gave the company a “hold” rating in a research note on Wednesday, December 10th. The Goldman Sachs Group upped their price objective on shares of Gilead Sciences from $110.00 to $115.00 and gave the stock a “neutral” rating in a report on Thursday, January 8th. Finally, Citigroup raised their target price on Gilead Sciences from $140.00 to $156.00 and gave the company a “buy” rating in a report on Tuesday, January 27th. One analyst has rated the stock with a Strong Buy rating, twenty-four have assigned a Buy rating and three have given a Hold rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $136.73.

Gilead Sciences Company Profile

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.